Ventyx Biosciences (NASDAQ:VTYX – Get Free Report) had its price objective dropped by investment analysts at HC Wainwright from $54.00 to $52.00 in a report released on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 55.69% from the company’s previous close.
A number of other equities research analysts also recently weighed in on the stock. Oppenheimer lowered their price objective on shares of Ventyx Biosciences from $62.00 to $57.00 in a research report on Friday. Credit Suisse Group assumed coverage on Ventyx Biosciences in a research report on Wednesday, June 14th. They set an “outperform” rating and a $63.00 price target on the stock. Finally, 500.com restated a “reiterates” rating on shares of Ventyx Biosciences in a research report on Friday, May 12th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $57.22.
Read Our Latest Analysis on Ventyx Biosciences
Ventyx Biosciences Stock Performance
Ventyx Biosciences (NASDAQ:VTYX – Get Free Report) last announced its quarterly earnings data on Thursday, August 10th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.20). During the same period in the previous year, the company posted ($0.39) earnings per share. As a group, research analysts forecast that Ventyx Biosciences will post -2.8 EPS for the current year.
Insider Buying and Selling at Ventyx Biosciences
In other news, insider William J. Sandborn sold 3,487 shares of the stock in a transaction on Monday, May 15th. The stock was sold at an average price of $36.47, for a total value of $127,170.89. Following the completion of the transaction, the insider now owns 34,662 shares of the company’s stock, valued at $1,264,123.14. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Ventyx Biosciences news, CEO Raju Mohan sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $34.36, for a total value of $1,030,800.00. Following the completion of the sale, the chief executive officer now directly owns 1,513,126 shares in the company, valued at $51,991,009.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider William J. Sandborn sold 3,487 shares of the stock in a transaction on Monday, May 15th. The shares were sold at an average price of $36.47, for a total value of $127,170.89. Following the transaction, the insider now directly owns 34,662 shares of the company’s stock, valued at $1,264,123.14. The disclosure for this sale can be found here. Insiders have sold 602,202 shares of company stock valued at $21,893,179 in the last quarter. Corporate insiders own 24.39% of the company’s stock.
Institutional Trading of Ventyx Biosciences
Hedge funds and other institutional investors have recently modified their holdings of the company. Credit Suisse AG grew its stake in shares of Ventyx Biosciences by 161.9% in the 2nd quarter. Credit Suisse AG now owns 36,882 shares of the company’s stock worth $1,210,000 after purchasing an additional 22,798 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Ventyx Biosciences by 57.5% in the second quarter. BlackRock Inc. now owns 3,226,572 shares of the company’s stock valued at $105,832,000 after buying an additional 1,177,971 shares in the last quarter. Ameritas Investment Partners Inc. lifted its position in shares of Ventyx Biosciences by 93.7% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,865 shares of the company’s stock valued at $127,000 after acquiring an additional 1,870 shares during the last quarter. State Board of Administration of Florida Retirement System bought a new stake in shares of Ventyx Biosciences during the 2nd quarter worth $436,000. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Ventyx Biosciences by 30.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 88,840 shares of the company’s stock worth $2,914,000 after acquiring an additional 20,561 shares during the last quarter.
About Ventyx Biosciences
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
Read More
- Five stocks we like better than Ventyx Biosciences
- Best Stocks Under $10.00
- MarketBeat Week in Review – 8/7 – 8/11
- What is the S&P 500 and How It is Distinct from Other Indexes
- 3 Retailers To Watch Closely Next Week
- What Are Defense Contractor Stocks? How to Invest in Defense
- Investing in Coffee: 3 Great Strategies to Consider
Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
